Anbio Tech (NNNN): Bathi resik saben saham (EPS TTM)

Anbio Biotechnology's transition to biodegradable materials in diagnostics serves as a key growth driver. The current annual net income per unit illustrates this trend, where 0.16 represents the current level of the metric. However, strict FDA regulations and price dumping are constraining the business, although high customer loyalty to proprietary reagents ensures a steady flow of capital.

Anbio Biotechnology (NNNN) is building its pipeline through academic alliances, which makes current revenue dependent on the efficiency of joint research. The rolling annual earnings per share trend reflects net earnings per share adjusted for the impact of issuances, allowing investors to assess the stability of the company's fundamental income amid a prolonged sideways trend and identify opportunity cost risks in a timely manner.